Autologous HB-adMSCs is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. Lead sponsors include Hope Biosciences Research Foundation (1) and Hope Biosciences LLC (1). Registered phase: Phase 2. Conditions studied include Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis; Traumatic Brain Injury.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05951777 | Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury (ClinicalTrials.gov ↗) Traumatic Brain Injury |
Phase 2 | Recruiting |
| NCT06800404 | "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" (ClinicalTrials.gov ↗) Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsing Remitting Multiple Sclerosis (RRMS) | 1 |
| Multiple Sclerosis | 1 |
| Traumatic Brain Injury | 1 |
| Lead sponsor | Trials |
|---|---|
| Hope Biosciences Research Foundation | 1 |
| Hope Biosciences LLC | 1 |
| Register | Autologous HB-adMSCs trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Autologous HB-adMSCs works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Autologous HB-adMSCs (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.